Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Josse A. Depla"'
Autor:
Pamela E. Capendale, Inés García-Rodríguez, Anoop T. Ambikan, Lance A. Mulder, Josse A. Depla, Eline Freeze, Gerrit Koen, Carlemi Calitz, Vikas Sood, Renata Vieira de Sá, Ujjwal Neogi, Dasja Pajkrt, Adithya Sridhar, Katja C. Wolthers
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Picornaviruses are a leading cause of central nervous system (CNS) infections. While genotypes such as parechovirus A3 (PeV-A3) and echovirus 11 (E11) can elicit severe neurological disease, the highly prevalent PeV-A1 is not associated with
Externí odkaz:
https://doaj.org/article/bda8e7616a1141d5a3a550360afea61c
Autor:
Lance A. Mulder, Josse A. Depla, Adithya Sridhar, Katja Wolthers, Dasja Pajkrt, Renata Vieira de Sá
Publikováno v:
Stem Cell Research & Therapy, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Background The first human brain organoid protocol was presented in the beginning of the previous decade, and since then, the field witnessed the development of many new brain region-specific models, and subsequent protocol adaptations and m
Externí odkaz:
https://doaj.org/article/7240263d2b1b4f7ba69ff35d032ae700
Autor:
Adithya Sridhar, Josse A. Depla, Lance A. Mulder, Eveliina Karelehto, Lieke Brouwer, Leonie Kruiswijk, Renata Vieira de Sá, Adam Meijer, Melvin M. Evers, Frank J. M. van Kuppeveld, Dasja Pajkrt, Katja C. Wolthers
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 5 (2022)
ABSTRACT Enterovirus D68 (EV-D68) is an RNA virus that can cause outbreaks of acute flaccid paralysis (AFP), a polio-like disease. Before 2010, EV-D68 was a rare pathogen associated with mild respiratory symptoms, but the recent EV-D68 related increa
Externí odkaz:
https://doaj.org/article/21f27dcb3b52466392561c972a72bd2c
Autor:
Josse A. Depla, Marina Sogorb-Gonzalez, Lance A. Mulder, Vivi M. Heine, Pavlina Konstantinova, Sander J. van Deventer, Katja C. Wolthers, Dasja Pajkrt, Adithya Sridhar, Melvin M. Evers
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 167-175 (2020)
The development of gene therapies for central nervous system disorders is challenging because it is difficult to translate preclinical data from current in vitro and in vivo models to the clinic. Therefore, we developed induced pluripotent stem cell
Externí odkaz:
https://doaj.org/article/6801bff942ae41f78c9545db8a90bbd9
Autor:
Sonay Keskin, Cynthia C. Brouwers, Marina Sogorb-Gonzalez, Raygene Martier, Josse A. Depla, Astrid Vallès, Sander J. van Deventer, Pavlina Konstantinova, Melvin M. Evers
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss , Pp 275-284 (2019)
Huntington disease (HD) is a fatal neurodegenerative genetic disorder, thought to reflect a toxic gain of function in huntingtin (Htt) protein. Adeno-associated viral vector serotype 5 (AAV5)- microRNA targeting huntingtin (miHTT) is a HD gene-therap
Externí odkaz:
https://doaj.org/article/ea22fa55f85944d198f8e622dca8256f
Autor:
Josse A. Depla, Lance A. Mulder, Renata Vieira de Sá, Morgane Wartel, Adithya Sridhar, Melvin M. Evers, Katja C. Wolthers, Dasja Pajkrt
Publikováno v:
Viruses, Vol 14, Iss 3, p 634 (2022)
Pathogenesis of viral infections of the central nervous system (CNS) is poorly understood, and this is partly due to the limitations of currently used preclinical models. Brain organoid models can overcome some of these limitations, as they are gener
Externí odkaz:
https://doaj.org/article/99eaeac497774dd88a19833bdda866c5
Autor:
Astrid Vallès, Sander J. H. van Deventer, Cynthia Brouwers, Marina Sogorb-Gonzalez, Raygene Martier, Sonay Keskin, Melvin M. Evers, Pavlina Konstantinova, Josse A. Depla
Publikováno v:
Molecular therapy. Methods & clinical development, 15, 275-284. Nature Publishing Group
Molecular Therapy-Methods and Clinical Development, 15, 275-284. CELL PRESS
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss, Pp 275-284 (2019)
Molecular Therapy-Methods and Clinical Development, 15, 275-284. CELL PRESS
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss, Pp 275-284 (2019)
Huntington disease (HD) is a fatal neurodegenerative genetic disorder, thought to reflect a toxic gain of function in huntingtin (Htt) protein. Adeno-associated viral vector serotype 5 (AAV5)- microRNA targeting huntingtin (miHTT) is a HD gene-therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e52587067d908691c8a40a13c635bd1
https://doi.org/10.1016/j.omtm.2019.09.010
https://doi.org/10.1016/j.omtm.2019.09.010
Autor:
Pavlina Konstantinova, Lance A. Mulder, Katja C. Wolthers, Marina Sogorb-Gonzalez, Josse A. Depla, Melvin M. Evers, Dasja Pajkrt, Vivi M. Heine, Adithya Sridhar, Sander J. H. van Deventer
Publikováno v:
Depla, J A, Sogorb-Gonzalez, M, Mulder, L A, Heine, V M, Konstantinova, P, van Deventer, S J, Wolthers, K C, Pajkrt, D, Sridhar, A & Evers, M M 2020, ' Cerebral Organoids : A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain ', Molecular Therapy-Methods and Clinical Development, vol. 18, pp. 167-175 . https://doi.org/10.1016/j.omtm.2020.05.028
Molecular therapy. Methods & clinical development, 18, 167-175. Nature Publishing Group
Molecular Therapy-Methods and Clinical Development, 18, 167-175. Cell Press
Molecular Therapy-Methods and Clinical Development, 18, 167-175. CELL PRESS
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 167-175 (2020)
Molecular Therapy-Methods and Clinical Development
Molecular Therapy. Methods & Clinical Development
Molecular Therapy-Methods & Clinical Development
Molecular therapy. Methods & clinical development, 18, 167-175. Nature Publishing Group
Molecular Therapy-Methods and Clinical Development, 18, 167-175. Cell Press
Molecular Therapy-Methods and Clinical Development, 18, 167-175. CELL PRESS
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 167-175 (2020)
Molecular Therapy-Methods and Clinical Development
Molecular Therapy. Methods & Clinical Development
Molecular Therapy-Methods & Clinical Development
The development of gene therapies for central nervous system disorders is challenging because it is difficult to translate preclinical data from current in vitro and in vivo models to the clinic. Therefore, we developed induced pluripotent stem cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867ea54c5c6c8998bc318699c7d7dcaa
https://hdl.handle.net/1887/3185409
https://hdl.handle.net/1887/3185409
Autor:
Pavlina Konstantinova, Sonay Keskin, Astrid Vallès, Marina Sogorb-Gonzalez, Cynthia Brouwers, Melvin M. Evers, Josse A. Depla, Sander J. H. van Deventer, Raygene Martier
Publikováno v:
Experimental therapeutics – preclinical.
Background We are developing an HTT lowering approach based on adeno-associated serotype 5 virus carrying an expression cassette of an engineered therapeutic microRNA (AAV5-miHTT). Main efficacy and safety concerns with microRNA gene therapy approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3bb0b77dab5c9a88bff3e2bfde1ba8b
https://doi.org/10.1136/jnnp-2018-ehdn.242
https://doi.org/10.1136/jnnp-2018-ehdn.242